Mirum Pharmaceuticals定价6亿美元高级票据

• Mirum Pharmaceuticals (MIRM) priced a private offering of $600M aggregate principal amount of 0.00% convertible senior notes due 2032.
• The initial purchasers have a 13-day option to buy up to an additional $90M notes.
• Mirum plans to use about $475M proceeds plus roughly 3.2M shares to exchange approximately $237.2M principal amount of its existing 4.00% convertible senior notes due 2029 and remaining for general corporate purposes.
• The offering is expected to close on May 15, 2026.
• The stock price traded about 2.3% lower on Wednesday during pre-market trade.

More on Mirum Pharmaceuticals

• Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
• Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
• Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta - Slideshow
• Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch
• Mirum Pharmaceuticals GAAP EPS of -$13.43 misses by $13.06, revenue of $159.9M beats by $11.69M